Ablate, or not to ablate left atrial low-voltage areas in atrial fibrillation patients?
European Heart Journal Open · 01.07.2026 · 6 (4)
DOI: 10.1093/ehjopen/oeag112 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Heart Journal Open, online erschienen am 23.07.2026. Verfasst von Roberto De Ponti und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Insubria, Via Guicciardini, 9, Varese 21100, Italy. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This correspondence refers to ‘Win ratio analysis of low-voltage area ablation in persistent atrial fibrillation: sub-analysis of SUPPRESS-AF’, by A. Sunaga et al. https://doi.org/10.1093/ehjopen/oeag024 The authors’ response is available at: https://doi.org/10.1093/ehjopen/oeag113 We read with interest the paper by Sunaga et al.1 that presents the results of a sub-analysis of the SUPPRESS-AF randomized trial on left atrial low-voltage ablation (LVA) in patients undergoing the first ablation for persistent atrial fibrillation (AF). Their results echo one of the main studies that assessed no additional benefit in terms of arrhythmia recurrences by adjunctive ablation of LVAs beyond pulmonary vein isolation (PVI) in patients with persistent AF. Additionally, the win ratio analysis adopted in this sub-study shows no improvement in clinical outcomes considered in a hierarchical sequence prioritizing safety. With the acknowledged limitation that the study was powered to evaluate only the primary endpoint (arrhythmia recurrences), leading to a low number of clinical events comprised secondary endpoints, it should also be considered that the results of a win ratio analysis are inherently influenced by pre-specified analytical choices, including the hierarchy and order of outcomes, the number of considered outcomes, and how ties are handled. Indeed, this study brings up the dilemma of whether additional ablation of LVA beyond PVI could be beneficial in AF patients without increasing complications and unnecessary procedure prolongation. Currently, ablation of LVAs—generally defined as areas with a peak-to-peak bipolar voltage ≤0.5 mV at high-density electroanatomic mapping in sinus rhythm—is an area of uncertainty, rarely performed in first procedures and in paroxysmal cases. In general, the need for adjunctive ablation reflects that in some cases the outcome of PVI, regardless of the energy used, does not meet expectations. If, on one hand, the use of ablation earlier in patients’ history and the removal of risk factors will lead in the future to a reduced burden of atrial cardiomyopathy, on the other, in some patients currently referred for AF ablation, extensive atrial remodeling limits the results of a conservative procedure. Notably, atrial cardiomyopathy includes a complex anatomic and histologic remodeling altering the atrial wall in terms of both arrhythmogenicity and thrombogenicity. The presence of LVAs is per se associated with increased risk of atrial arrhythmia recurrences and cardiovascular events, including heart failure and stroke, in the follow-up after PVI-only procedure.2 Furthermore, the presence of fibroblasts and other non-myocyte cells, observed in atrial cardiomyopathy and detected as LVAs, can be arrhythmogenic based not only on conduction delay or block but also on the cross-talk between myocytes and non-myocyte cells that can perturb the electrical activity of the myocardium. Finally, even minimal extension of the LVAs is associated with altered mechanical and electrical left atrial function. In fact, AF patients with minimal LVAs (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Insubria, Via Guicciardini, 9, Varese 21100, Italy.
- Department of Medical Sciences, University of Turin, Corso Dogliotti, 14, Turin 10126, Italy.
- Division of Cardiology, Cardiovascular and Thoracic Department, "Città della Salute e della Scienza" Hospital, Corso Bramante 88, Turin 10126, Italy.
ORCID-Profile: Roberto De Ponti, Matteo Anselmino
Zitieren
APA
De Ponti, R., Griffith Brookles, C., & Anselmino, M. (2026). Ablate, or not to ablate left atrial low-voltage areas in atrial fibrillation patients?. European Heart Journal Open, 6(4). https://doi.org/10.1093/ehjopen/oeag112
Vancouver
De Ponti R, Griffith Brookles C, Anselmino M. Ablate, or not to ablate left atrial low-voltage areas in atrial fibrillation patients?. European Heart Journal Open. 2026;6(4). doi:10.1093/ehjopen/oeag112
BibTeX
@article{DePonti2026,
author = {De Ponti, Roberto and Griffith Brookles, Carola and Anselmino, Matteo},
title = {Ablate, or not to ablate left atrial low-voltage areas in atrial fibrillation patients?},
journal = {European Heart Journal Open},
year = {2026},
volume = {6},
number = {4},
doi = {10.1093/ehjopen/oeag112}
}
EUVIMED